Laura Hales was one of three panelists at an event sponsored by ENET titled “SBIR grants and non-dilutive funding to bootstrap your startup company”.
Founder Laura Hales speaks on a panel about Extend Biosciences’ non-dilutive funding path
Extend Biosciences is awarded a Phase II SBIR grant from NIDDK
Extend Biosciences’ long-acting PTH molecule will advance through IND-enabling studies with a Phase II grant from NIDDK.
NIDDK awards Extend Biosciences with a Phase I grant
Extend Biosciences was awarded a Phase I SBIR grant to advance their long-acting insulin molecule for the treatment of diabetes.
Founder Laura Hales speaks on a panel sponsored by The Capital Network
At an event titled “SBIR – America’s Largest Seed Fund”, Extend Biosciences founder Laura Hales spoke about her experience winning SBIR grants.
A Panel on Women Entrepreneurs in STEM features founder Laura Hales
Founder Laura Hales was one of four female entrepreneurs featured on a panel titled “She Prevailed – The Secretes to Start-up Success in STEM from Women Entrepreneurs”. The panel was sponsored by AWIS and also featured Patrice Milos, Ailis Tweed-Kent, and Teresa Nelson, and was moderated by Joanne Kamens.
Extend Biosciences is awarded a Phase II SBIR grant from NCI
Extend Biosciences was awarded a Phase II SBIR grant from the National Cancer Institute to fund efficacy and IND-enabling studies for a long-acting ghrelin molecule for cancer cachexia.
Extend Biosciences has been awarded a third patent
Extend Biosciences’ third patent has been awarded by the USPTO. The patent, titled “Insulin Vitamin D Conjugates” issued April 11, 2017 (US 9,616,109).
Founder Laura Hales wins the WIB Lobster Pot pitch competition
In a Shark Tank-style event sponsored by Women In Bio, Extend Biosciences founder Laura Hales, Ph.D. won first prize (an All-Clad Lobster Pot!) in the pitch competition in front of >100 audience members and 4 investors. The event, held at LabCentral, featured 6 companies pitching from life sciences and healthcare, and was moderated by Marian Nakada of JJDC.
Extend Biosciences is awarded a Phase I grant from NIAID
Extend Biosciences was awarded a Phase I SBIR grant from the National Institute of Allergy and Infectious Disease to work on a program for acute radiation syndrome.
Extend Biosciences says goodbye to LabCentral
Extend Biosciences has completed their 3-year maximum stay at LabCentral and said goodbye to fellow residents and staff at a happy hour in the playroom with Advirna. On February 1, Extend Bio will move to a shared laboratory facility in Newton.